The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy

FEBS Journal

Volumn 280, Issue 17, 2013, Pages 4210-4229

  Marshall, Jamie L ^a   Kwok, Yukwah ^a   McMorran, Brian J ^a,b   Baum, Linda G ^a,b   Crosbie Watson, Rachelle H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Duchenne; dystrophin; integrin; laminin binding; mdx; muscle; muscular dystrophy; sarcolemma; sarcospan; utrophin

Indexed keywords

ALPHA SARCOGLYCAN; ALPHA7 INTEGRIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA DYSTROGLYCAN; BETA1 INTEGRIN; BMN 195; BORTEZOMIB; CHAPERONE; CURCUMIN; DYSTROPHIN; DYSTROPHIN GLYCOPROTEIN COMPLEX; FUKUTIN RELATED PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; MLN 273; PARVOVIRUS VECTOR; PROTEASOME; SARCOGLYCAN; SARCOSPAN; SMT C 1100; UNCLASSIFIED DRUG; UTROPHIN; UTROPHIN GLYCOPROTEIN COMPLEX;

ACTIN FILAMENT; ADENO ASSOCIATED VIRUS; DIAPHRAGM; DRUG DELIVERY SYSTEM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; ENZYME REPLACEMENT; EXTRACELLULAR MATRIX; HEART; HUMAN; MUSCLE CELL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SARCOLEMMA; UPREGULATION;

DUCHENNE; DYSTROPHIN; INTEGRIN; LAMININ-BINDING; MDX; MUSCLE; MUSCULAR DYSTROPHY; SARCOLEMMA; SARCOSPAN; UTROPHIN;

ANIMALS; CARRIER PROTEINS; DYSTROPHIN; HUMANS; INTEGRINS; MEMBRANE PROTEINS; MUSCULAR DYSTROPHIES; NEOPLASM PROTEINS; SARCOLEMMA; SIGNAL TRANSDUCTION; UTROPHIN;

EID: 84882617523     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12295     Document Type: Review

References (181)

1. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, &, Campbell KP, (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319.
2. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, &, Kunkel LM, (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.
3. Hoffman EP, Brown RH Jr, &, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
4. Levine BA, Moir AJ, Patchell VB, &, Perry SV, (1990) The interaction of actin with dystrophin. FEBS Lett 263, 159-162.
5. Campbell KP, &, Kahl SD, (1989) Association of dystrophin and an integral membrane glycoprotein. Nature 338, 259-262.
6. Moorwood C, (2008) Syncoilin, an intermediate filament-like protein linked to the dystrophin associated protein complex in skeletal muscle. Cell Mol Life Sci 65, 2957-2963.
7. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, &, Victor RG, (2000) Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 97, 13818-13823.
8. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, et al,. (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 119, 624-635.
9. Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, &, Adams ME, (2003) Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ Res 92, 554-560.
10. Thomas GD, &, Victor RG, (1998) Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J Physiol 506, 817-826.
11. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE, Gurudevan SV, Anene F, Elashoff RM, Thomas GD, et al,. (2012) Tadalafil alleviates muscle ischemia in patients with becker muscular dystrophy. Sci Transl Med 4, 162ra155.
12. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, &, Sweeney HL, (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90, 3710-3714.
13. Ervasti JM, &, Campbell KP, (1991) Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121-1131.
14. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, &, Campbell KP, (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696-702.
15. Ervasti JM, &, Campbell KP, (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122, 809-823.
16. Ervasti JM, Kahl SD, &, Campbell KP, (1991) Purification of dystrophin from skeletal muscle. J Biol Chem 266, 9161-9165.
17. Ervasti JM, &, Campbell KP, (1993) Dystrophin and the membrane skeleton. Curr Opin Cell Biol 5, 82-87.
18. Yoshida M, &, Ozawa E, (1990) Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 108, 748-752.
19. Crosbie RH, Lebakken CS, Holt KH, Venzke DP, Straub V, Lee JC, Grady RM, Chamberlain JS, Sanes JR, &, Campbell KP, (1999) Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex. J Cell Biol 145, 153-165.
20. Crosbie RH, Lim LE, Moore SA, Hirano M, Hays AP, Maybaum SW, Collin H, Dovico SA, Stolle CA, Fardeau M, et al,. (2000) Molecular and genetic characterization of sarcospan: insights into sarcoglycan-sarcospan interactions. Hum Mol Genet 9, 2019-2027.
21. Holt KH, &, Campbell KP, (1998) Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem 273, 34667-34670.
22. Weller B, Karpati G, &, Carpenter S, (1990) Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 100, 9-13.
23. Pearce M, Blake DJ, Tinsley JM, Byth BC, Campbell L, Monaco AP, &, Davies KE, (1993) The utrophin and dystrophin genes share similarities in genomic structure. Hum Mol Genet 2, 1765-1772.
24. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight AE, Kendrick-Jones J, Suthers GK, Love DR, et al,. (1992) Primary structure of dystrophin-related protein. Nature 360, 591-593.
25. Hynes RO, (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
26. Song WK, Wang W, Foster RF, Bielser DA, &, Kaufman SJ, (1992) H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis. J Cell Biol 117, 643-657.
27. von der Mark H, Durr J, Sonnenberg A, von der Mark K, Deutzmann R, &, Goodman SL, (1991) Skeletal myoblasts utilize a novel beta 1-series integrin and not alpha 6 beta 1 for binding to the E8 and T8 fragments of laminin. J Biol Chem 266, 23593-23601.
28. Balci B, Uyanik G, Dincer P, Gross C, Willer T, Talim B, Haliloglu G, Kale G, Hehr U, Winkler J, et al,. (2005) An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 15, 271-275.
29. Bonnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan DJ, Angelini C, &, Hoffman EP, (1995) Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet 11, 266-273.
30. Matsumura K, Tome FM, Collin H, Azibi K, Chaouch M, Kaplan JC, Fardeau M, &, Campbell KP, (1992) Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 359, 320-322.
31. McNally EM, Bonnemann CG, Kunkel LM, &, Bhattacharya SK, (1996) Deficiency of adhalin in a patient with muscular dystrophy and cardiomyopathy. N Engl J Med 334, 1610-1611.
32. McNally EM, Passos-Bueno MR, Bonnemann CG, Vainzof M, de Sa Moreira E, Lidov HG, Othmane KB, Denton PH, Vance JM, Zatz M, et al,. (1996) Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 59, 1040-1047.
33. McNally EM, Duggan D, Gorospe JR, Bonnemann CG, Fanin M, Pegoraro E, Lidov HG, Noguchi S, Ozawa E, Finkel RS, et al,. (1996) Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum Mol Genet 5, 1841-1847.
34. Nigro V, de Sa Moreira E, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos-Bueno MR, &, Zatz M, (1996) Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 14, 195-198.
35. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, Yamamoto H, Bonnemann CG, Gussoni E, Denton PH, et al,. (1995) Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 270, 819-822.
36. van Reeuwijk J, Janssen M, van den Elzen C, Beltran-Valero de Bernabe D, Sabatelli P, Merlini L, Boon M, Scheffer H, Brockington M, Muntoni F, et al,. (2005) POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 42, 907-912.
37. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, Inazu T, Mitsuhashi H, Takahashi S, Takeuchi M, et al,. (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 1, 717-724.
38. Hayashi YK, Chou FL, Engvall E, Ogawa M, Matsuda C, Hirabayashi S, Yokochi K, Ziober BL, Kramer RH, Kaufman SJ, et al,. (1998) Mutations in the integrin alpha7 gene cause congenital myopathy. Nat Genet 19, 94-97.
39. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C, Khalil N, Feng L, Saran RK, Voit T, Merlini L, et al,. (2003) Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 12, 2853-2861.
40. Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, &, North KN, (2001) The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 38, 649-657.
41. Mercuri E, Yuva Y, Brown SC, Brockington M, Kinali M, Jungbluth H, Feng L, Sewry CA, &, Muntoni F, (2002) Collagen VI involvement in Ullrich syndrome: a clinical, genetic, and immunohistochemical study. Neurology 58, 1354-1359.
42. Tome FM, Evangelista T, Leclerc A, Sunada Y, Manole E, Estournet B, Barois A, Campbell KP, &, Fardeau M, (1994) Congenital muscular dystrophy with merosin deficiency. CR Acad Sci III 317, 351-357.
43. Durbeej M, &, Campbell KP, (2002) Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 12, 349-361.
44. Fassler R, &, Meyer M, (1995) Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev 9, 1896-1908.
45. Williamson RA, Henry MD, Daniels KJ, Hrstka RF, Lee JC, Sunada Y, Ibraghimov-Beskrovnaya O, &, Campbell KP, (1997) Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet 6, 831-841.
46. Crosbie RH, Heighway J, Venzke DP, Lee JC, &, Campbell KP, (1997) Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. J Biol Chem 272, 31221-31224.
47. Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, Lee J, Peter AK, Martin PT, &, Crosbie-Watson RH, (2012) Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Biol 197, 1009-1027.
48. Peter AK, Marshall JL, &, Crosbie RH, (2008) Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex. J Cell Biol 183, 419-427.
49. Hoffman EP, Knudson CM, Campbell KP, &, Kunkel LM, (1987) Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 330, 754-758.
50. Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AH, Belfall B, Klamut HJ, Talbot J, Hodges RS, Ray PN, &, Worton RG, (1988) The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 333, 466-469.
51. Miike T, Miyatake M, Zhao J, Yoshioka K, &, Uchino M, (1989) Immunohistochemical dystrophin reaction in synaptic regions. Brain Dev 11, 344-346.
52. Samitt CE, &, Bonilla E, (1990) Immunocytochemical study of dystrophin at the myotendinous junction. Muscle Nerve 13, 493-500.
53. Zhao J, Yoshioka K, Miyatake M, &, Miike T, (1992) Dystrophin and a dystrophin-related protein in intrafusal muscle fibers, and neuromuscular and myotendinous junctions. Acta Neuropathol 84, 141-146.
54. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, &, Campbell KP, (1992) Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 360, 588-591.
55. Prochniewicz E, Henderson D, Ervasti JM, &, Thomas DD, (2009) Dystrophin and utrophin have distinct effects on the structural dynamics of actin. Proc Natl Acad Sci USA 106, 7822-7827.
56. Rybakova IN, Humston JL, Sonnemann KJ, &, Ervasti JM, (2006) Dystrophin and utrophin bind actin through distinct modes of contact. J Biol Chem 281, 9996-10001.
57. Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, Davies KE, Chamberlain JS, &, Duan D, (2010) Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci 123, 2008-2013.
58. Durko M, Allen C, Nalbantoglu J, &, Karpati G, (2010) CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres. J Muscle Res Cell Motil 31, 181-193.
59. Nguyen HH, Jayasinha V, Xia B, Hoyte K, &, Martin PT, (2002) Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 99, 5616-5621.
60. Xia B, Hoyte K, Kammesheidt A, Deerinck T, Ellisman M, &, Martin PT, (2002) Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. Dev Biol 242, 58-73.
61. Legate KR, Montanez E, Kudlacek O, &, Fassler R, (2006) ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 7, 20-31.
62. Hannigan G, Troussard AA, &, Dedhar S, (2005) Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5, 51-63.
63. Wu C, (2005) PINCH, N(i)ck and the ILK: network wiring at cell-matrix adhesions. Trends Cell Biol 15, 460-466.
64. McDonald PC, Fielding AB, &, Dedhar S, (2008) Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 121, 3121-3132.
65. Gheyara AL, Vallejo-Illarramendi A, Zang K, Mei L, St-Arnaud R, Dedhar S, &, Reichardt LF, (2007) Deletion of integrin-linked kinase from skeletal muscles of mice resembles muscular dystrophy due to alpha 7 beta 1-integrin deficiency. Am J Pathol 171, 1966-1977.
66. Smirnov SP, McDearmon EL, Li S, Ervasti JM, Tryggvason K, &, Yurchenco PD, (2002) Contributions of the LG modules and furin processing to laminin-2 functions. J Biol Chem 277, 18928-18937.
67. Talts JF, Mann K, Yamada Y, &, Timpl R, (1998) Structural analysis and proteolytic processing of recombinant G domain of mouse laminin alpha2 chain. FEBS Lett 426, 71-76.
68. Talts JF, Andac Z, Gohring W, Brancaccio A, &, Timpl R, (1999) Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 18, 863-870.
69. Holmberg J, &, Durbeej M, (2013) Laminin-211 in skeletal muscle function. Cell Adh Migr 7, 111-121.
70. Gawlik KI, &, Durbeej M, (2011) Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies. Skelet Muscle 1, 9.
71. Tanabe Y, Esaki K, &, Nomura T, (1986) Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta Neuropathol 69, 91-95.
72. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, &, Sanes JR, (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729-738.
73. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, &, Davies KE, (1997) Utrophin-dystrophin- deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727.
74. Rooney JE, Welser JV, Dechert MA, Flintoff-Dye NL, Kaufman SJ, &, Burkin DJ, (2006) Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin. J Cell Sci 119, 2185-2195.
75. Guo C, Willem M, Werner A, Raivich G, Emerson M, Neyses L, &, Mayer U, (2006) Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 15, 989-998.
76. Liu J, Milner DJ, Boppart MD, Ross RS, &, Kaufman SJ, (2012) beta1D chain increases alpha7beta1 integrin and laminin and protects against sarcolemmal damage in mdx mice. Hum Mol Genet 21, 1592-1603.
77. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, &, Davies K, (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4, 1441-1444.
78. Poysky J, (2007) Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8-9 December 2006, Philadelphia, USA. Neuromuscul Disord 17, 986-994.
79. Perronnet C, Chagneau C, Le Blanc P, Samson-Desvignes N, Mornet D, Laroche S, De La Porte S, &, Vaillend C, (2012) Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice. Hum Mol Genet 21, 2263-2276.
80. Goyenvalle A, Seto JT, Davies KE, &, Chamberlain J, (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20, R69-R78.
81. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, et al,. (2010) Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363, 1429-1437.
82. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A, et al,. (2011) Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE 6, e19189.
83. Casar JC, McKechnie BA, Fallon JR, Young MF, &, Brandan E, (2004) Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient mice. Dev Biol 268, 358-371.
84. Lechner BE, Lim JH, Mercado ML, &, Fallon JR, (2006) Developmental regulation of biglycan expression in muscle and tendon. Muscle Nerve 34, 347-355.
85. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, &, Fallon JR, (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108, 762-767.
86. Goudenege S, Lamarre Y, Dumont N, Rousseau J, Frenette J, Skuk D, &, Tremblay JP, (2010) Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy. Mol Ther 18, 2155-2163.
87. Rooney JE, Gurpur PB, Yablonka-Reuveni Z, &, Burkin DJ, (2009) Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy. Am J Pathol 174, 256-264.
88. Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, &, Burkin DJ, (2012) Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol 180, 1593-1602.
89. Rooney JE, Gurpur PB, &, Burkin DJ, (2009) Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci USA 106, 7991-7996.
90. Marshall JL, Chou E, Oh J, Kwok A, Burkin DJ, &, Crosbie-Watson RH, (2012) Dystrophin and utrophin expression require sarcospan: loss of alpha7 integrin exacerbates a newly discovered muscle phenotype in sarcospan-null mice. Hum Mol Genet 21, 4378-4393.
91. Han R, Kanagawa M, Yoshida-Moriguchi T, Rader EP, Ng RA, Michele DE, Muirhead DE, Kunz S, Moore SA, Iannaccone ST, et al,. (2009) Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc Natl Acad Sci USA 106, 12573-12579.
92. Moghadaszadeh B, Albrechtsen R, Guo LT, Zaik M, Kawaguchi N, Borup RH, Kronqvist P, Schroder HD, Davies KE, Voit T, et al,. (2003) Compensation for dystrophin-deficiency: ADAM12 overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins. Hum Mol Genet 12, 2467-2479.
93. Galliano MF, Huet C, Frygelius J, Polgren A, Wewer UM, &, Engvall E, (2000) Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, alpha-actinin-2, is required for myoblast fusion. J Biol Chem 275, 13933-13939.
94. Kronqvist P, Kawaguchi N, Albrechtsen R, Xu X, Schroder HD, Moghadaszadeh B, Nielsen FC, Frohlich C, Engvall E, &, Wewer UM, (2002) ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice. Am J Pathol 161, 1535-1540.
95. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, &, Fujisawa-Sehara A, (1995) A metalloprotease-disintegrin participating in myoblast fusion. Nature 377, 652-656.
96. Grewal PK, &, Hewitt JE, (2002) Mutation of Large, which encodes a putative glycosyltransferase, in an animal model of muscular dystrophy. Biochim Biophys Acta 1573, 216-224.
97. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, &, Kaufman SJ, (2001) Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 152, 1207-1218.
98. Mercuri E, &, Muntoni F, (2012) The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol 72, 9-17.
99. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, Celli J, van Beusekom E, van der Zwaag B, Kayserili H, Merlini L, Chitayat D, Dobyns WB, et al,. (2002) Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 71, 1033-1043.
100. Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y, Herrmann R, Sperner J, Korenke C, Diesen C, et al,. (2004) Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet 41, e61.
101. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, Ponting CP, Estournet B, Romero NB, Mercuri E, et al,. (2001) Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 69, 1198-1209.
102. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, Segawa M, Yoshioka M, Saito K, Osawa M, et al,. (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394, 388-392.
103. Roscioli T, Kamsteeg EJ, Buysse K, Maystadt I, van Reeuwijk J, van den Elzen C, van Beusekom E, Riemersma M, Pfundt R, Vissers LE, et al,. (2012) Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of alpha-dystroglycan. Nat Genet 44, 581-585.
104. Silan F, Yoshioka M, Kobayashi K, Simsek E, Tunc M, Alper M, Cam M, Guven A, Fukuda Y, Kinoshita M, et al,. (2003) A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol 53, 392-396.
105. van Reeuwijk J, Brunner HG, &, van Bokhoven H, (2005) Glyc-O-genetics of Walker-Warburg syndrome. Clin Genet 67, 281-289.
106. van Reeuwijk J, Grewal PK, Salih MA, Beltran-Valero de Bernabe D, McLaughlan JM, Michielse CB, Herrmann R, Hewitt JE, Steinbrecher A, Seidahmed MZ, et al,. (2007) Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome. Hum Genet 121, 685-690.
107. Willer T, Lee H, Lommel M, Yoshida-Moriguchi T, de Bernabe DB, Venzke D, Cirak S, Schachter H, Vajsar J, Voit T, et al,. (2012) ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet 44, 575-580.
108. Stevens E, Carss KJ, Cirak S, Foley AR, Torelli S, Willer T, Tambunan DE, Yau S, Brodd L, Sewry CA, et al,. (2013) Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of alpha-dystroglycan. Am J Hum Genet 92, 354-365.
109. Barone R, Aiello C, Race V, Morava E, Foulquier F, Riemersma M, Passarelli C, Concolino D, Carella M, Santorelli F, et al,. (2012) DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann Neurol 72, 550-558.
110. Lefeber DJ, Schonberger J, Morava E, Guillard M, Huyben KM, Verrijp K, Grafakou O, Evangeliou A, Preijers FW, Manta P, et al,. (2009) Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am J Hum Genet 85, 76-86.
111. Lefeber DJ, de Brouwer AP, Morava E, Riemersma M, Schuurs-Hoeijmakers JH, Absmanner B, Verrijp K, van den Akker WM, Huijben K, Steenbergen G, et al,. (2011) Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet 7, e1002427.
112. Manzini MC, Tambunan DE, Hill RS, Yu TW, Maynard TM, Heinzen EL, Shianna KV, Stevens CR, Partlow JN, Barry BJ, et al,. (2012) Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet 91, 541-547.
113. Vuillaumier-Barrot S, Bouchet-Seraphin C, Chelbi M, Devisme L, Quentin S, Gazal S, Laquerriere A, Fallet-Bianco C, Loget P, Odent S, et al,. (2012) Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am J Hum Genet 91, 1135-1143.
114. Jurado LA, Coloma A, &, Cruces J, (1999) Identification of a human homolog of the Drosophila rotated abdomen gene (POMT1) encoding a putative protein O-mannosyl-transferase, and assignment to human chromosome 9q34.1. Genomics 58, 171-180.
115. Willer T, Amselgruber W, Deutzmann R, &, Strahl S, (2002) Characterization of POMT2, a novel member of the PMT protein O-mannosyltransferase family specifically localized to the acrosome of mammalian spermatids. Glycobiology 12, 771-783.
116. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, Madson M, Oldstone MB, Schachter H, Wells L, &, Campbell KP, (2010) O-Mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327, 88-92.
117. Brockington M, Torelli S, Prandini P, Boito C, Dolatshad NF, Longman C, Brown SC, &, Muntoni F, (2005) Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy. Hum Mol Genet 14, 657-665.
118. Kanagawa M, Saito F, Kunz S, Yoshida-Moriguchi T, Barresi R, Kobayashi YM, Muschler J, Dumanski JP, Michele DE, Oldstone MB, et al,. (2004) Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117, 953-964.
119. Inamori K, Yoshida-Moriguchi T, Hara Y, Anderson ME, Yu L, &, Campbell KP, (2012) Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 335, 93-96.
120. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, Herrmann R, Anderson LV, Bashir R, Burgunder JM, et al,. (2001) Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 10, 2851-2859.
121. Shridas P, &, Waechter CJ, (2006) Human dolichol kinase, a polytopic endoplasmic reticulum membrane protein with a cytoplasmically oriented CTP-binding site. J Biol Chem 281, 31696-31704.
122. Maeda Y, Tanaka S, Hino J, Kangawa K, &, Kinoshita T, (2000) Human dolichol-phosphate-mannose synthase consists of three subunits, DPM1, DPM2 and DPM3. EMBO J 19, 2475-2482.
123. Maeda Y, Tomita S, Watanabe R, Ohishi K, &, Kinoshita T, (1998) DPM2 regulates biosynthesis of dolichol phosphate-mannose in mammalian cells: correct subcellular localization and stabilization of DPM1, and binding of dolichol phosphate. EMBO J 17, 4920-4929.
124. Burda P, &, Aebi M, (1999) The dolichol pathway of N-linked glycosylation. Biochim Biophys Acta 1426, 239-257.
125. Manya H, Chiba A, Yoshida A, Wang X, Chiba Y, Jigami Y, Margolis RU, &, Endo T, (2004) Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci USA 101, 500-505.
126. Buysse K, Riemersma M, Powell G, van Reeuwijk J, Chitayat D, Roscioli T, Kamsteeg EJ, van den Elzen C, van Beusekom E, Blaser S, et al,. (2013) Missense mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum Mol Genet 22, 1746-1754.
127. Dobson CM, Hempel SJ, Stalnaker SH, Stuart R, &, Wells L, (2012) O-Mannosylation and human disease. Cell Mol Life Sci doi: 10.1007/s00018-012- 1193-0.
128. Yis U, Uyanik G, Heck PB, Smitka M, Nobel H, Ebinger F, Dirik E, Feng L, Kurul SH, Brocke K, et al,. (2011) Fukutin mutations in non-Japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-Walker-Warburg phenotype. Neuromuscul Disord 21, 20-30.
129. Hehr U, Uyanik G, Gross C, Walter MC, Bohring A, Cohen M, Oehl-Jaschkowitz B, Bird LM, Shamdeen GM, Bogdahn U, et al,. (2007) Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease. Neurogenetics 8, 279-288.
130. Brockington S, &, Clarke A, (2001) The relative influence of temperature and food on the metabolism of a marine invertebrate. J Exp Mar Bio Ecol 258, 87-99.
131. Smith PL, &, Lowe JB, (1994) Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. J Biol Chem 269, 15162-15171.
132. Deconinck N, Tinsley J, De Backer F, Fisher R, Kahn D, Phelps S, Davies K, &, Gillis JM, (1997) Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat Med 3, 1216-1221.
133. Gilbert R, Nalbantoglu J, Petrof BJ, Ebihara S, Guibinga GH, Tinsley JM, Kamen A, Massie B, Davies KE, &, Karpati G, (1999) Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 10, 1299-1310.
134. Rafael JA, Tinsley JM, Potter AC, Deconinck AE, &, Davies KE, (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19, 79-82.
135. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, &, Davies KE, (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349-353.
136. Xu R, Chandrasekharan K, Yoon JH, Camboni M, &, Martin PT, (2007) Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol 171, 181-199.
137. Xu R, DeVries S, Camboni M, &, Martin PT, (2009) Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. Am J Pathol 175, 235-247.
138. Singhal N, Xu R, &, Martin PT, (2012) Distinct contributions of Galgt1 and Galgt2 to carbohydrate expression and function at the mouse neuromuscular junction. Mol Cell Neurosci 51, 112-126.
139. Cabrera PV, Pang M, Marshall JL, Kung R, Nelson SF, Stalnaker SH, Wells L, Crosbie-Watson RH, &, Baum LG, (2012) High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin binding. J Biol Chem 287, 22759-22770.
140. Santha E, Sperlagh B, Zelles T, Zsilla G, Toth PT, Lendvai B, Baranyi M, &, Vizi ES, (2000) Multiple cellular mechanisms mediate the effect of lobeline on the release of norepinephrine. J Pharmacol Exp Ther 294, 302-307.
141. Dwoskin LP, &, Crooks PA, (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 63, 89-98.
142. Wilhelm CJ, Johnson RA, Eshleman AJ, &, Janowsky A, (2008) Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem Pharmacol 75, 1411-1415.
143. Lee WC, Kang D, Causevic E, Herdt AR, Eckman EA, &, Eckman CB, (2010) Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones. J Neurosci 30, 5489-5497.
144. Bulfield G, Siller WG, Wight PA, &, Moore KJ, (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81, 1189-1192.
145. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, &, Barnard PJ, (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580.
146. Chamberlain JS, Pearlman JA, Muzny DM, Gibbs RA, Ranier JE, Caskey CT, &, Reeves AA, (1988) Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. Science 239, 1416-1418.
147. Chelly J, Gilgenkrantz H, Lambert M, Hamard G, Chafey P, Recan D, Katz P, de la Chapelle A, Koenig M, Ginjaar IB, et al,. (1990) Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 63, 1239-1248.
148. Ginjaar IB, Bakker E, van Paassen MM, den Dunnen JT, Wessels A, Zubrzycka-Gaarn EE, Moorman AF, &, van Ommen GJ, (1991) Immunohistochemical studies show truncated dystrophins in the myotubes of three fetuses at risk for Duchenne muscular dystrophy. J Med Genet 28, 505-510.
149. Jones BR, Brennan S, Mooney CT, Callanan JJ, McAllister H, Guo LT, Martin
150. Helliwell TR, Ellis JM, Mountford RC, Appleton RE, &, Morris GE, (1992) A truncated dystrophin lacking the C-terminal domains is localized at the muscle membrane. Am J Hum Genet 50, 508-514.
151. Jung D, Yang B, Meyer J, Chamberlain JS, &, Campbell KP, (1995) Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem 270, 27305-27310.
152. Banks GB, Gregorevic P, Allen JM, Finn EE, &, Chamberlain JS, (2007) Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum Mol Genet 16, 2105-2113.
153. Imamura M, Araishi K, Noguchi S, &, Ozawa E, (2000) A sarcoglycan-dystroglycan complex anchors Dp116 and utrophin in the peripheral nervous system. Hum Mol Genet 9, 3091-3100.
154. Cox GA, Sunada Y, Campbell KP, &, Chamberlain JS, (1994) Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 8, 333-339.
155. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, et al,. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418, 417-422.
156. Tachikawa M, Kanagawa M, Yu CC, Kobayashi K, &, Toda T, (2012) Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration. J Biol Chem 287, 8398-8406.
157. Singh S, &, Aggarwal BB, (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270, 24995-25000.
158. Monici MC, Aguennouz M, Mazzeo A, Messina C, &, Vita G, (2003) Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60, 993-997.
159. Pan Y, Chen C, Shen Y, Zhu CH, Wang G, Wang XC, Chen HQ, &, Zhu MS, (2008) Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 25, 531-537.
160. Durham WJ, Arbogast S, Gerken E, Li YP, &, Reid MB, (2006) Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34, 298-303.
161. Soheili T, Gicquel E, Poupiot J, N'Guyen L, Le Roy F, Bartoli M, &, Richard I, (2012) Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications. Hum Mutat 33, 429-439.
162. Wang F, Song W, Brancati G, &, Segatori L, (2011) Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J Biol Chem 286, 43454-43464.
163. Schlesinger MJ, (1990) Heat shock proteins. J Biol Chem 265, 12111-12114.
164. Bornman L, Polla BS, Lotz BP, &, Gericke GS, (1995) Expression of heat-shock/stress proteins in Duchenne muscular dystrophy. Muscle Nerve 18, 23-31.
165. Stary CM, Walsh BJ, Knapp AE, Brafman D, &, Hogan MC, (2008) Elevation in heat shock protein 72 mRNA following contractions in isolated single skeletal muscle fibers. Am J Physiol Regul Integr Comp Physiol 295, R642-R648.
166. Carmeli E, Beiker R, Maor M, &, Kodesh E, (2010) Increased iNOS, MMP-2, and HSP-72 in skeletal muscle following high-intensity exercise training. J Basic Clin Physiol Pharmacol 21, 127-146.
167. Gehrig SM, van der Poel C, Sayer TA, Schertzer JD, Henstridge DC, Church JE, Lamon S, Russell AP, Davies KE, Febbraio MA, et al,. (2012) Hsp72 preserves muscle function and slows progression of severe muscular dystrophy. Nature 484, 394-398.
168. Glickman MH, &, Ciechanover A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373-428.
169. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, &, Lisanti MP, (2007) Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 6, 1242-1248.
170. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, &, Lisanti MP, (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 163, 1663-1675.
171. Selsby J, Morris C, Morris L, &, Sweeney L, (2012) A proteasome inhibitor fails to attenuate dystrophic pathology in mdx mice. PLoS Curr 4, e4f84a944d8930.
172. Braakman I, &, Bulleid NJ, (2011) Protein folding and modification in the mammalian endoplasmic reticulum. Annu Rev Biochem 80, 71-99.
173. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, et al,. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68, 629-638.
174. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, &, Clark KR, (2012) Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 527, 90-99.
175. Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, &, Chamberlain JS, (2004) Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10, 671-678.
176. Zincarelli C, Soltys S, Rengo G, Koch WJ, &, Rabinowitz JE, (2010) Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 3, 81-89.
177. Brennan KJ, &, Hardeman EC, (1993) Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. J Biol Chem 268, 719-725.
178. Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, Silva O, Wang RT, Martinez L, Lu QL, Damoiseaux R, et al,. (2012) Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med 4, 164ra160.
179. Marshall JL, &, Watson RH, (2013) Sarcospan: a small protein with large potential for Duchenne muscular dystrophy. Skelet Muscle 3, 1.
180. Kim MH, Kay DI, Rudra RT, Chen BM, Hsu N, Izumiya Y, Martinez L, Spencer MJ, Walsh K, Grinnell AD, et al,. (2011) Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. Hum Mol Genet 20, 1324-1338.
181. Peter AK, Ko CY, Kim MH, Hsu N, Ouchi N, Rhie S, Izumiya Y, Zeng L, Walsh K, &, Crosbie RH, (2009) Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy. Hum Mol Genet 18, 318-327.